Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Apontis Pharma AG's
Operating Income
for the
six
months ended in Jun. 2025 was €0.81 Mil. Apontis Pharma AG's Interest Expense for the
six
months ended in Jun. 2025 was €0.00 Mil.
Apontis Pharma AG has no debt.
The higher the ratio, the stronger the company's financial strength is.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Apontis Pharma AG's Interest Coverage or its related term are showing as below:
FRA:APPH'
s Interest Coverage Range Over the Past 10 Years
Min: 4.11 Med: 43.43 Max: No Debt
Current: 30.8
FRA:APPH's Interest Coverage is not ranked
in the Drug Manufacturers industry.
Industry Median: 12.78
vs FRA:APPH: 30.80
Apontis Pharma AG (FRA:APPH) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Apontis Pharma AG Interest Coverage Related Terms
Apontis Pharma AG Interest Coverage Historical Data
* Premium members only.
The historical data trend for Apontis Pharma AG's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:APPH vs ZTS, UTHR, NBIX: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Apontis Pharma AG (FRA:APPH) has a Interest Coverage of No Debt (1) as of Jun. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Apontis Pharma AG and its competitors. This is 98% below median its historical median of 43.43. Over the past decade, Apontis Pharma AG's Interest Coverage has ranged from 4.11 to 10,000.00.
Is Apontis Pharma AG's Interest Coverage too high?
Apontis Pharma AG's current Interest Coverage of No Debt (1) is 98% below median its 10-year median of 43.43. Over the past 10 years, this metric has ranged from a low of 4.11 to a high of 10,000.00. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's Interest Coverage compare to ZTS and UTHR?
Apontis Pharma AG's Interest Coverage of No Debt (1) can be compared against companies in the Drug Manufacturers industry. The industry median Interest Coverage is 12.78. Historically, Apontis Pharma AG's own Interest Coverage has ranged from 4.11 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Apontis Pharma AG and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apontis Pharma AG's current Interest Coverage is No Debt (1), which is 98% below median its own 10-year median of 43.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current Interest Coverage of No Debt (1). The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current Interest Coverage is No Debt (1), which is 98% below median its 10-year median of 43.43. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current Interest Coverage is No Debt (1) as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?
Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued.
The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.
Key valuation signals for FRA:APPH:
Interest Coverage: No Debt (1) (98% below median its 10-year median of 43.43)
GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score
Get the complete analysis for FRA:APPH
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APPH has been successfully added to your 
